LSK Investment logo

LSK Investment

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Description

LSK Investment is a Korean venture capital firm that provides long-term capital and management support to venture enterprises.

Investor Profile

LSK Investment has backed more than 3 startups, with 1 new investments in the last 12 months alone. The firm has led 1 rounds, about 33% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Seed rounds (top funding stages).
  • Majority of deals are located in South Korea.
  • Strong thematic focus on Biotechnology, Genetics, Health Care.

Stage Focus

  • Series A (33%)
  • Series B (33%)
  • Seed (33%)

Country Focus

  • South Korea (67%)

Industry Focus

  • Biotechnology
  • Genetics
  • Health Care
  • Medical
  • Pharmaceutical
  • Product Research
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LSK Investment frequently co-invest with?

JB Ventures
Asia, Kyonggi-do, South Korea, Dongan
Co-Investments: 1
DI
North America, Texas, United States, Houston
Co-Investments: 1
B
North America, Illinois, United States, Ohio
Co-Investments: 1
Stonebridge Capital
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
UTC Investment Co.
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Woori Bank
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Sejong Venture Partners
North America, New Jersey, United States, Fort Lee
Co-Investments: 1

What are some of recent deals done by LSK Investment?

Trioar

Daejeon, Taejon-jikhalsi, South Korea

Trioar is a biotechnological research company that manufacture pharmaceutical products and drugs.

BiopharmaBiotechnologyPharmaceutical
Series BJul 17, 2025
Amount Raised: $16,163,094

saas

SeedNov 20, 2024
Amount Raised: $1,300,000
Autotelic Bio

Cheongju, Ch'ungch'ong-bukto, South Korea

Autotelic Bio is a bio technology company that researches and develops anti-cancer drugs.

BiotechnologyPharmaceuticalProduct Research
Series BMar 28, 2022
Amount Raised: $12,665,468
Medizen Humancare

Songpadong, Seoul-t'ukpyolsi, South Korea

disease risk analysis service using genetic chip or analysis kit and specific disease-related genome variation package .

BiotechnologyGeneticsHealth CareMedical
Series AJan 1, 2014
Amount Raised: $8,700,000